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• Advanced heart failure patients who are implanted with left ventricular assist devices 
(LVADs) have a unique circulation that is characterised by a reduced or even absent 
arterial pulse. 
• The remarkable survival of these patients is accompanied by circulatory complications, 
including stroke, gastro-intestinal bleeding and right-heart failure. 
• Understanding the mechanisms related to the complications in LVAD patients will help 




Some humans with chronic, advanced heart failure are surgically implanted with a left 
ventricular assist device (LVAD). Because the LVAD produces a continuous flow, a pulse is 
often absent in these patients. This allows for a unique investigation of the human circulation 
and a controversy around the ‘need’ for a pulse. This medical debate also generates a more 
generic, fundamental discussion into what is ‘normal’ arterial physiology & health. The 
comprehensive study and understanding of the arterial responses to drastically altered 
haemodynamics due to CF-LVADs, at rest and during activity, presents an opportunity to 
significantly increase our current understanding of the fundamental components of arterial 
regulation (flow, blood pressure, sympathetic activity, endothelial function, pulsatility) in a 
way that could never have been studied previously. In a series of four articles, we summarise 
the talks presented at the symposium entitled “Bionic Women and Men – Physiology lessons 
from implantable cardiac devices” during the 2019 Annual Meeting of The Physiological 
Society in Aberdeen, Scotland. The articles highlight the novel questions generated by 
physiological phenomena observed in LVAD patients and proposes future areas of interest 




Whilst knowledge of the human circulation has increased substantially over the past centuries, 
its interdependence with the heart and the local factors that govern arterial function in health 
and disease warrant ongoing study. The staggering prevalence of hypertension further 
emphasises the need to advance our current knowledge of the factors that govern the interaction 
between the heart and local arterial flow (McDonnell et al., 2019). For most of human history, 
attempts to comprehend the impact of drastically altered flow characteristics in vivo have been 
limited because manipulation of the source of flow dynamics, the heart, is challenging. 
However, the recent advent of left ventricular assist devices (LVADs) as a therapy for advanced 
heart failure patients has created new opportunities for investigation. In this first article of a 
series of four, we introduce ‘LVAD patients’ and their remarkable, unique physiology, discuss 
the current knowledge surrounding the presence of a non-physiologic pulse, and postulate new 
hypotheses in cardiovascular science that arise from the special insight these bionic women 
and men gift us. 
Who are the “Bionic Women and Men”? 
In some heart failure patients, the disease progresses unfavourably with conventional medical 
therapy. Although the preferred next step would be a heart transplant, in most countries there 
are not enough donor hearts available. For these patients, the surgical implantation of an LVAD 
is the best option, and the successes of recent clinical trials are testimony to the success of this 
medical feat (see Figure 1, Colombo et al., 2018; Mehra et al., 2018; Mehra et al., 2019). These 
patients are not only ‘bionic’ because they walk around with a metal pump in their hearts, the 
continuous flow produced by the mechanical pumps also changes the flow characteristics 
typically produced by the native heart – LVAD patients live “without a pulse” (Purohit et al., 
2018). This unique physiological state can be detected in large and medium-sized arteries and 
varies between patients as explained in more detail in Figure 2 (Castagna et al., 2017). 
Accordingly, there has been much debate around the role of the arterial pulse (Cornwell et al., 
2015; Floras et al., 2015; Cornwell et al., 2019; Stöhr et al., 2019). The fact that the overall 
health of LVAD patients continues to improve suggests that humans may not need a pulse to 
live. Conversely, other data indicate that the complications LVAD patients experience may be 
linked to the low pulse, and that the reduced pulsatility may be as detrimental as the increased 
pulsatility in hypertensive patients (Ambardekar et al., 2015; Cornwell III et al., 2015) The 
following paragraph discusses the clinical complications that LVAD patients experience that 
may be attributable to the absent pulse. 
Clinical presentation of LVAD Patients 
Historically, patients with advanced heart failure who did not receive a heart transplant were 
surgically implanted with pulsatile heart pumps. The prognosis of these patients was relatively 
poor and was only improved when continuous-flow LVADs emerged (Slaughter et al., 2009). 
The recent MOMENTUM 3 trial shows a further improved survival and a much-reduced rate 
of stroke in LVAD patients (Mehra et al., 2017; Uriel et al., 2017; Colombo et al., 2018; Mehra 
et al., 2018; Mehra et al., 2019). Interestingly, the lower rate of strokes was not attributed to 
blood pressure (Colombo et al., 2018), suggesting that the contribution of blood pressure to 
stroke may be different in patients with a continuous-flow circulation. This has implications 
for the risk factors for stroke in the general population as it is currently believed that an 
increased blood pressure is a major risk factor for stroke (Seshadri et al., 2001).  
A second complications in LVAD patients is the high prevalence of gastrointestinal bleeding 
that suggests that the continuous-flow circulation impacts clotting factors and/or disruption of 
the integrity of the arterial wall. The necessary anti-coagulation regimen may contribute to GI 
bleeding as well as the development of angiodysplasia, although the latter may originate 
already in heart failure and only manifest itself in GI bleeding during LVAD support (Patel et 
al., 2018). Additionally,  degradation of the von Willebrand factor, which typically “mediates 
platelet adhesion to both the subendothelial matrix and endothelial surfaces and acts as a carrier 
for coagulation factor VIII in the circulation” (Starke et al., 2011) has been widely reported in 
LVAD patients (Bartoli et al., 2014; Nascimbene et al., 2016; Bartoli et al., 2018). This has 
been largely attributed to the altered conformation of the high-molecular-weight-multimers 
caused during the passage of blood through the bearings of the mechanical pumps and may be 
an important contributor to the increased prevalence of GI bleeding as well as microcirculatory 
bleeds in the brain of continuous-flow, second generation LVAD patients (Yoshioka et al., 
2017). One study has proposed the intriguing idea that an increased arterial pulsatility can 
counter the vWF degradation caused by the passage of blood through the mechanical bearings 
of the LVAD (Vincent et al., 2018). Since the HM3 LVAD is generally thought to reduce 
mechanical shear, the idea by Vincent and colleagues  fits the report of a greater preservation 
of the von Willebrand Factor in HM3 patients compared with HMII (Netuka et al., 2016). 
However, the incidence of GI bleeding remains similar between HMII and HM3 patients and 
the true peripheral pulsatility, including that in the microcirculation, of both HMII and HM3 
patients remains to be unveiled. To identify the mechanisms for altered bleeding is thus of great 
importance and we speculate that the same mechanisms that lead to GI bleeding may also be 
responsible for non-thrombotic, haemorrhagic strokes in LVAD patients (Lai et al., 2019). 
Solving this riddle, perhaps via a combination of in vivo and mock-loop investigations similar 
to the ones reported by Vincent and colleagues (2018), will undoubtedly advance the current 
understanding of the interaction between arterial flow dynamics and haemostasis, which has 
implications for numerous medical conditions. 
The third major complication encountered by LVAD patients is right-heart failure. This 
typically occurs early following LVAD implantation and is associated with a particularly poor 
prognosis. Although numerous determinants for this phenomenon have been proposed, the true 
cause of right-heart failure in LVAD patients remains to be determined. As such, this 
phenomenon directly links to a number of other fundamental (patho-)physiological phenomena 
such as pulmonary hypertension, exercise-induced right heart problems and venous congestion 
in advanced heart failure. Interestingly, increased suction from the LVAD does not seem to 
impact pulmonary artery pressures as much as it affects right ventricular volume, as elegant 
data by Addetia and colleagues show (Addetia et al., 2018). Consequently, it is possible that 
the occurrence of right heart failure may be reduced by a more gradual increase in LVAD speed 
to slowly accustom the right ventricle to the increased volumetric load. In general, the insight 
from the sudden improvement in left sided output because of the LVAD with the simultaneous 
impact on the right ventricle provides new knowledge into the regulation of right heart function 
and pulmonary artery pressures beyond the specific LVAD condition.  
The Role of Pulsatility 
Many of the factors discussed above can be related to the reduction or even total absence of 
pulsatility. Whilst an increased pulse pressure has been associated with an increased risk of 
morbidity and mortality, it is also known that low arterial flow pulsatility disrupts normal 
arterial processes. As reported previously, “Pulsatility of flow causes cyclical stretch of the 
arterial wall that is a critical contributor to endothelial production of nitric oxide and 
cardiovascular health (Hahn & Schwartz, 2009). The high occurrence of bleeding events such 
as GI bleeding and haemorrhagic strokes indicate a primary problem with endothelial integrity” 
(Stöhr et al., 2019). In other words, pulsatility may not just be important because it is the natural 
state of the human cardiovascular system - a fait accompli argument that is often read in articles 
or heard at conferences. Rather, studies on the physiology show that there are clear biological 
processes that depend on a minimum amount of pulsatility to optimise arterial function and 
health. For example, pulsatility releases the vasoactive nitric oxide, thus contributing to the 
ability of the artery to respond adequately to circulatory changes (Nakano et al., 2000). Equally, 
too much pulsatility appears has been associated with a greater risk of cardiovascular disease 
(Chuang et al., 2016). Although the impact of the ‘artificial pulse’ in HM3 patients it not 
known, it is possible that some of the clinical and functional improvements in these patients 
may be attributed to an overall improved biology because of a moderately increased pulsatility. 
That said, it is unknown at this time whether the automated modulations in the HM3 rotor speed 
translate into any meaningful pulse throughout the circulation. Of course, in the context of a 
continuous-flow circulation that constantly pushes blood forward through the system, a normal 
pulsatility may also not be beneficial, since too much pulsatility may be transported into the 
microcirculation of end-organs (Webb et al., 2012; Stöhr et al., 2018). This effect may be even 
worse in LVAD patients with increased arterial stiffness (Patel et al., 2017; Rosenblum et al., 
2018), likely impacting on the brain and GI tract as well as the right heart. It can be expected 
that the study of the complex interactions between the heart, arterial blood pressure, pulsatility 
and stiffness in LVAD patients will reveal new insight into the mechanisms that impact 
cardiovascular health in all humans.  
Links to further material 
- A podcast on a conversation with an LVAD patient and a researcher can be listened to here. 
- The “HIT-LVAD” project has material on its ResearchGate website. 
- An open access article can be found here. 
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Figure 1. Anatomical position and function of a left ventricular assist device (LVAD). The 
inflow graft of a mechanical pump is surgically connected to the patients’ LV apex. Through 
the suction of the pump, the LV is unloaded, and some blood is redirected via the outflow graft 
into the ascending aorta. Note: This figure was previously published in ‘Fully Magnetically Levitated Left 
Ventricular Assist System for Treating Advanced HF’, Ivan Netuka et al, Journal of the American College of 
Cardiology, Elsevier, Volume 66, Issue 23, 15 December 2015, Pages 2579-2589, 





Figure 2. Hemodynamics in the healthy circulation and in patients with different left 
ventricular assist devices (LVADs). The different flow profiles depend on the type of LVAD 
and whether the patients’ aortic valve opens during contraction of the LV. Pulsatility in the 
whole circulation is in part caused by the volume added by the native heart (if the valve opens), 
but a considerable amount of pulsatility is also generated through the continuous-flow pump 
itself because of fluctuations in intra-ventricular pressure that alter the pressure-gradient 
between the LVAD inflow and outflow graft (see Pagani, 2008 for more details). Note: A similar 
version of this figure created by the same author (EJS) was previously published in ‘The Unique Blood Pressures 
and Pulsatility of LVAD Patients: Current Challenges and Future Opportunities’ from Castagna, F., Stöhr, E.J., 
Pinsino, A. et al. Curr Hypertens Rep (2017) 19: 85. https://doi.org/10.1007/s11906-017- 0782- 6 and is under the 
Creative Commons Attribution 4.0 International Licence. 
 
